Abu Dhabi's Financial Hub Is Full, Yet Empty Desks Are Aplenty
The contradiction stems from the emirate's push to compete with business hubs in neighboring Dubai and globally. As part of that effort, firms were encouraged to establish a local presence and relocate more staff. The proximity to Abu Dhabi's influential wealth funds, which control nearly $2 trillion, added to the appeal. The campaign has drawn top banks and private markets firms, earning ADGM, the financial center, a reputation as the Gulf's ' hedge fund island.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
US to hold more than 30 offshore oil and gas auctions through 2040
(Reuters) -U.S. President Donald Trump's administration on Tuesday unveiled a comprehensive schedule to hold more than 30 offshore oil and gas lease sales in the Gulf of Mexico and Alaska's Cook Inlet over the next 15 years. WHY IT'S IMPORTANT The plan fulfills a directive in Trump's One Big Beautiful Bill Act, which passed last month, and is aligned with his administration's energy dominance agenda to boost domestic fossil fuel production. The schedule marks a significant departure from former President Joe Biden, whose administration had planned for a historically small number of drilling rights auctions as part of its efforts to address climate change. KEY QUOTE "The One Big Beautiful Bill Act is a landmark step toward unleashing America's energy potential," Interior Secretary Doug Burgum said in a statement. "Under President Trump's leadership, we're putting in place a bold, long-term program that strengthens American Energy Dominance, creates good-paying jobs and ensures we continue to responsibly develop our offshore resources." BY THE NUMBERS The schedule includes 30 lease sales through 2040 in the Gulf of Mexico, which Trump has renamed the Gulf of America. The first Gulf sale is set for Dec. 10 of this year. Starting next year, there will be two sales in the Gulf annually through 2039 and one in 2040. Six lease sales are planned for Alaska's Cook Inlet through 2032. The first will be held in March of 2026.
Yahoo
3 hours ago
- Yahoo
Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders
Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's orphan indication products, resulting in non-dilutive funding for Jaguar SAN FRANCISCO, CA / / August 19, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Annual Meeting of Stockholders held on August 19, 2025 (the "Annual Meeting"). Seven proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Annual Meeting and supplemental information filed with the Securities and Exchange Commission on July 21, 2025 and as amended on August 6, 2025. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at The proxy statement is also available on the Company's corporate website. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Canalevia-CA1, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the August 2025 Emerging Growth Conference, and statements regarding Jaguar's planned regulatory pathway to complete a supplemental NDA for crofelemer for patients with metastatic breast cancer. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Mastercard in a Spree to Boost Cross-Border Payments in the UAE
Mastercard Incorporated MA and Worldpay recently teamed up to leverage Mastercard Move and enhance money movement for consumers and businesses in the UAE. As part of this partnership, Worldpay's Push-to-Card solution will facilitate swift and seamless domestic and international card-based payouts. These include diverse use cases such as gig worker payments, insurance settlements, remittances and crypto withdrawals — all underpinned by Mastercard's strong security framework and reliable infrastructure. For consumers, this means faster access to their money, while businesses gain streamlined and more efficient payout capabilities, without the need to exchange banking details. Additionally, the solution enables Worldpay's merchants to use their existing acquiring flows to fund disbursements, simplifying processes and minimizing dependence on multiple service providers. A few days before the latest initiative, Mastercard and an UAE-based fintech Zand entered into a strategic partnership. Through the utilization of Mastercard Move's money movement solutions, the collaboration will allow Zand to deliver secure, seamless and efficient international money transfer services to its customers. Such initiatives reflect Mastercard's sincere efforts to enhance cross-border payment capabilities across the UAE and accelerate the adoption of digital transactions nationwide. Mastercard Move empowers banks, non-bank financial institutions and their customers—including direct disbursers—with secure, near-instant money transfer solutions, both within countries and across borders. The suite of solutions covers more than 200 countries, supports 150+ currencies, and reaches more than 95% of the world's banked population. The increased usage of Mastercard Move is expected to boost its cross-border volumes, which advanced 15% on a local currency basis in the second quarter of 2025. How are Competitors Faring? Some of Mastercard's competitors across the UAE include PayPal Holdings, Inc. PYPL and Visa Inc. V. PayPal boasts a significant presence in the UAE. This April, PYPL opened its first Middle East and Africa hub in Dubai, serving 80 countries. The site will boost cross-border commerce and empower businesses with AI-driven payments. Its cross-border total payment volume grew 10% year over year in the second quarter of 2025. Visa operates in the UAE and functions as a payment network, facilitating transactions for various financial institutions and their customers within the country. V cards are widely accepted throughout the UAE for both retail purchases and online transactions. Visa's cross-border volume improved 12% year over year in the third quarter of fiscal 2025. Mastercard's Price Performance, Valuation & Estimates Shares of Mastercard have gained 24.5% in the past year compared with the industry's 19.3% growth. Image Source: Zacks Investment Research From a valuation standpoint, MA trades at a forward price-to-earnings ratio of 32.44, above the industry average of 21.61. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Mastercard's 2025 earnings implies a 11.7% rise from the year-ago period. The consensus mark for revenues indicates 15.1% year-over-year growth. Image Source: Zacks Investment Research MA currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Mastercard Incorporated (MA) : Free Stock Analysis Report Visa Inc. (V) : Free Stock Analysis Report PayPal Holdings, Inc. (PYPL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
